<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">2983306R</journal-id>
<journal-id journal-id-type="pubmed-jr-id">3565</journal-id>
<journal-id journal-id-type="nlm-ta">Epilepsia</journal-id>
<journal-id journal-id-type="iso-abbrev">Epilepsia</journal-id>
<journal-title-group>
<journal-title>Epilepsia</journal-title>
</journal-title-group>
<issn pub-type="ppub">0013-9580</issn>
<issn pub-type="epub">1528-1167</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29750358</article-id>
<article-id pub-id-type="pmc">5990455</article-id>
<article-id pub-id-type="doi">10.1111/epi.14087</article-id>
<article-id pub-id-type="manuscript">NIHMS957620</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A population-based cost-effectiveness study of early genetic testing in severe epilepsies of infancy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Howell</surname>
<given-names>Katherine B.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Eggers</surname>
<given-names>Stefanie</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dalziel</surname>
<given-names>Kim</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Riseley</surname>
<given-names>Jessica</given-names>
</name>
<degrees>BSc</degrees>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mandelstam</surname>
<given-names>Simone</given-names>
</name>
<degrees>MBChB</degrees>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A5">5</xref>
<xref ref-type="aff" rid="A6">6</xref>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Myers</surname>
<given-names>Candace T.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McMahon</surname>
<given-names>Jacinta M.</given-names>
</name>
<degrees>BSc(Hons)</degrees>
<xref ref-type="aff" rid="A9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gen Couns</surname>
<given-names>Amy Schneider M</given-names>
</name>
<xref ref-type="aff" rid="A9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Carvill</surname>
<given-names>Gemma L.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mefford</surname>
<given-names>Heather C</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A8">8</xref>
</contrib>
<contrib contrib-type="author">
<collab>The Victorian Severe Epilepsy of Infancy Study Group</collab>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Scheffer</surname>
<given-names>Ingrid E.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A7">7</xref>
<xref ref-type="aff" rid="A9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Harvey</surname>
<given-names>A. Simon</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Department of Neurology, The Royal Children’s Hospital, Melbourne, Australia</aff>
<aff id="A2">
<label>2</label>Department of Paediatrics, The University of Melbourne, Melbourne, Australia</aff>
<aff id="A3">
<label>3</label>Murdoch Children’s Research Institute, Melbourne, Australia</aff>
<aff id="A4">
<label>4</label>Melbourne School of Global and Population Health, The University of Melbourne, Melbourne, Australia</aff>
<aff id="A5">
<label>5</label>Department of Medical Imaging, The Royal Children’s Hospital, Melbourne, Australia</aff>
<aff id="A6">
<label>6</label>Department of Radiology, The University of Melbourne, Melbourne, Australia</aff>
<aff id="A7">
<label>7</label>Florey Institute of Neuroscience and Mental Health, Melbourne, Australia</aff>
<aff id="A8">
<label>8</label>Division of Genetic Medicine, Department of Pediatrics, University of Washington, Seattle, USA</aff>
<aff id="A9">
<label>9</label>Department of Medicine, Epilepsy Research Centre, Austin Health, The University of Melbourne, Melbourne, Australia</aff>
<aff id="A10">
<label>10</label>The Ken and Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA</aff>
<author-notes>
<corresp id="FN1">Corresponding author: Dr Katherine Howell, Royal Children’s Hospital, 50 Flemington Rd, Parkville 3052, Australia, Phone: +61 3 9345 5661, <email>katherine.howell@rch.org.au</email></corresp>
<fn fn-type="COI-statement" id="FN4">
<p>
<bold>Declaration of interests</bold>
</p>
<p>Dr Howell was supported by the Gustav Nossal National Health and Medical Research Council (NHMRC) Postgraduate Scholarship and the Clifford PhD Scholarship. Dr Mefford is support by National Institutes of Health (NINDS R01 NS069605). Prof Scheffer is supported by a NHMRC Program Grant and Practitioner Fellowship. None of the authors has any conflicts of interest to disclose.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>9</day>
<month>4</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>11</day>
<month>5</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>6</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>6</month>
<year>2019</year>
</pub-date>
<volume>59</volume>
<issue>6</issue>
<fpage>1177</fpage>
<lpage>1187</lpage>
<!--elocation-id from pubmed: 10.1111/epi.14087-->
<abstract>
<title>Summary</title>
<sec id="S1">
<title>Objective</title>
<p id="P2">The severe epilepsies of infancy (SEI) are a devastating group of disorders that pose a major care and economic burden on society; early diagnosis is critical for optimal management. This study sought to determine the incidence and aetiologies of SEI, and model the yield and cost-effectiveness of early genetic testing.</p>
</sec>
<sec id="S2">
<title>Methods</title>
<p id="P3">Population-based study of the incidence, etiologies and cost-effectiveness of a whole exome sequencing-based gene panel (targeted-WES) in infants with SEI born 2011–2013, identified through EEG and neonatal databases. SEI was defined as seizure onset before age 18 months, frequent seizures, epileptiform EEG and failure of ≥2 anti-epileptic drugs. Medical records, investigations, MRIs and EEGs were analysed, and genetic testing performed if no etiology was identified. Economic modelling was performed to determine yield and cost-effectiveness of investigation of infants with unknown etiology at epilepsy onset, incorporating targeted-WES at different stages of the diagnostic pathway.</p>
</sec>
<sec id="S3">
<title>Results</title>
<p id="P4">Of 114 infants with SEI (incidence 54/100,000 live births/year), the etiology was determined in 76 (67%): acquired brain injuries (14), focal cortical dysplasias (14), other brain malformations (17), channelopathies (11), chromosomal (9), metabolic (6) and other genetic (5) disorders. Modelling showed that incorporating targeted-WES increased diagnostic yield compared to investigation without targeted-WES (48/86 vs 39/86). Early targeted-WES had lower total cost ($677,081USD vs $738,136USD) than late targeted-WES. A pathway with early targeted-WES and limited metabolic testing yielded seven additional diagnoses compared to investigation without targeted-WES (46/86 vs 39/86), with lower total cost ($455,597USD vs $661,103USD), lower cost per diagnosis ($9,904USD vs $16,951USD) and a dominant cost-effectiveness ratio.</p>
</sec>
<sec id="S4">
<title>Significance</title>
<p id="P5">Severe epilepsies occur in 1/2,000 infants, with the etiology identified in two-thirds, most commonly malformative. Early use of targeted-WES yields more diagnoses for lower cost. Early genetic diagnosis will enable timely administration of precision medicines, once developed, with the potential to improve long-term outcome.</p>
</sec>
</abstract>
<kwd-group>
<kwd>epilepsy</kwd>
<kwd>infancy</kwd>
<kwd>incidence</kwd>
<kwd>etiology</kwd>
<kwd>genomic</kwd>
<kwd>health economic</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>